STOCKSCOPE

Light & Wonder (ASX: LNW) Profit Jumps 17% Despite Falling Revenue. Can Its Cash Flow Momentum Last?

Danny Aad

Danny Aad

Technology & Biotechnology Specialist | StockScope

Published:9 Nov 2026
Light & Wonder (ASX: LNW) Profit Jumps 17% Despite Falling Revenue. Can Its Cash Flow Momentum Last?

Light & Wonder (ASX: LNW) has delivered a 17% increase in quarterly net profit despite declining revenue, highlighting a significant improvement in earnings efficiency. With operating cash flow climbing 28% and debt falling, the gaming technology group is demonstrating stronger financial discipline, although weakness in its SciPlay division and reduced earnings growth expectations present challenges.

Its latest quarterly results, released to the ASX on 5 November 2026, reveal a business increasingly focused on recurring revenue, premium gaming machines and debt reduction.

Key Numbers

  • Revenue: US$824 million for Q3 2026, down 2% year-on-year.
  • Net profit: US$133 million, up 17%, with diluted earnings per share increasing 28% to US$1.72.
  • Adjusted EBITDA: US$383 million, up 2%, representing a 46% margin.
  • Operating cash flow: US$236 million, up 28%, while adjusted free cash flow increased 21% to US$181 million.
  • Debt: US$5.02 billion in outstanding principal at 30 September 2026, with net debt leverage declining to 3.3 times.

Latest Results Highlight Stronger Earnings Efficiency

Light & Wonder's third-quarter performance demonstrates how an improving revenue mix and operating efficiency can strengthen profitability even when overall sales decline.

Gaming operations revenue increased 3% to US$248 million, while gaming machine sales climbed 5% to US$199 million.

The company's iGaming division delivered 13% revenue growth to US$97 million, supported by proprietary gaming content and expanding partnerships across North America.

However, SciPlay revenue declined 12% to US$173 million, reflecting continued weakness across the social casino market.

Gaming systems revenue also fell 24% to US$55 million, highlighting uneven demand across the broader gaming portfolio.

Management now expects full-year 2026 adjusted EBITDA growth towards the lower end of its previously forecast mid-to-high single-digit range.

What Stands Out: Stronger Cash Flow, but Growth Remains Uneven

The improvement in cash generation represents the most compelling financial development.

Operating cash flow increased from US$184 million to US$236 million, although favourable working capital timing and lower interest payments contributed to the improvement.

After US$90 million in capital expenditure, operating cash flow less capital expenditure totalled US$146 million.

This compares with the company's adjusted free cash flow measure of US$181 million, highlighting the importance of distinguishing underlying cash generation from adjusted financial measures.

Meanwhile, outstanding debt principal declined by US$153 million during the quarter.

We believe this improves financial flexibility, although substantial leverage remains a constraint on capital allocation.

Without a consistently dated market valuation and normalised earnings outlook, a precise fair-value estimate would be difficult to justify.

What Light & Wonder Is Doing Now

Light & Wonder continues expanding its premium gaming machine portfolio, with its North American premium installed base increasing by 2,657 units year-on-year.

This marked 25 consecutive quarters of premium installed-base growth, strengthening the company's recurring revenue foundation.

Its Grover charitable gaming business also added 1,487 units year-on-year, supporting further expansion in gaming operations.

Meanwhile, Matthieu Labbat became SciPlay chief executive on 4 November 2026, introducing new leadership to a division facing declining revenue and competitive pressure.

The company is also prioritising debt reduction while continuing investment in gaming content, product development and operational infrastructure.

Insight: Can Cash Flow Growth Offset SciPlay's Weakness?

We think Light & Wonder's established gaming distribution network, expanding recurring revenue and improving cash generation provide a credible foundation for long-term earnings growth. However, strong gaming operations contrast with SciPlay's continued contraction, while approximately US$5 billion in outstanding debt limits financial flexibility. The US$127.5 million Aristocrat intellectual property settlement earlier in 2026 also demonstrates the commercial consequences of content-related disputes. Sustained organic growth, stronger underlying free cash flow and further debt reduction would materially strengthen our assessment of the business.

What Happens Next?

Management is targeting net debt leverage towards 3.0 times by the end of 2026 and below 3.0 times during the first half of 2027.

The next important test will be fourth-quarter performance, particularly whether premium gaming machine demand and iGaming expansion can offset continued SciPlay weakness.

For shareholders, sustained cash generation, progress towards lower leverage and evidence of renewed revenue growth will determine whether Light & Wonder's stronger profitability represents a durable improvement in its financial outlook.

Danny Aad

Danny Aad

(Technology & Biotechnology Specialist | StockScope)

Danny Aad is an experienced technology executive with a distinguished career spanning more than three decades, including senior leadership positions as Chief Technology Officer (CTO) across the technology and biotechnology sectors. With extensive expertise in technology strategy, digital innovation and the evolving biotechnology landscape, Danny brings a wealth of industry knowledge and technical insight to his analysis of emerging technologies, corporate developments and investment opportunities.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

Viridis Mining (ASX: VMM) Signs Estimated US$915 Million Rare Earths Deal. Can It Turn Demand Into Profits?
Mining
Mining

Viridis Mining (ASX: VMM) Signs Estimated US$915 Million Rare Earths Deal. Can It Turn Demand Into Profits?

A binding rare earths offtake agreement representing an estimated US$915 million in minimum revenue has strengthened the commercial outlook for Viridis Mining and Minerals Limited ASX: VMM. ...

Alison ElzayedAlison Elzayed•
ANZ Group Holdings (ASX: ANZ) Delivers $7.59 Billion Profit, but Can Its $902 Million Cost-Cutting Success Last?
Financials
Financials

ANZ Group Holdings (ASX: ANZ) Delivers $7.59 Billion Profit, but Can Its $902 Million Cost-Cutting Success Last?

ANZ Group Holdings Limited ASX: ANZ has delivered a 31% increase in annual cash profit to $7.59 billion, supported by substantial cost reductions and improved operational efficiency. However...

Mark ElzayedMark Elzayed•
ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Loading more stories...